Il SerD come Point of Care per infezione da HCV: è possibile

Titolo Rivista MISSION
Autori/Curatori Liliana Praticò, Roberta Marenzi, Nicola Ghidelli, Andrea Corbetta, Marta Vairini, Michela Franzin, Stefano Fagiuoli, Paolo Donadoni, Marco Riglietta
Anno di pubblicazione 2022 Fascicolo 2022/58
Lingua Italiano Numero pagine 6 P. 12-17 Dimensione file 0 KB
DOI 10.3280/mis58-2022oa14792
Il DOI è il codice a barre della proprietà intellettuale: per saperne di più clicca qui

Vedi l'articolo Scarica l'articolo open access

FrancoAngeli è membro della Publishers International Linking Association, Inc (PILA)associazione indipendente e non profit per facilitare (attraverso i servizi tecnologici implementati da CrossRef.org) l’accesso degli studiosi ai contenuti digitali nelle pubblicazioni professionali e scientifiche

Introduction: The Addictive Behaviour Centre (Ser.D.) of Bergamo has been in the frontline to tackle HCV infection in patients who use drugs over the last few years. Methods: Several initiatives have been implemented, from the HCV screening performed for the IST screening and by using finger tests, up to the prescription of direct-acting antivirals (DAAs) in the Ser.D. point of care. Results: out of 584 patients tested for HCV Ab for the IST screening, 15,4% resulted positive, out of 191 patients tested for HCVRNA, 43,5% resulted positive. Out of 186 patients tested by the use of finger tests for HCV Ab, 18,8% resulted positive, while of the 303 patients tested by HCVRNA finger test, 21,5% was positive. 94 patients were found eligible for DAAs treatment: 31 already started the treatment, while 15 are going to start in the next months. Conclusion: The access to HCV care for people who use drugs has been improved by the introduction of point of care testing and the DAAs treatment in the Ser.D. of Bergamo. Unfortunately, there are still barriers to treatment that need to be addressed for this vulnerable group of people.;

  1. World Health Organization (2017). Action plan for the health sector response to viral hepatitis in the WHO European Region.
  2. (2) Regione Lombardia (2021). -- Text available at the website: www.regione.lombardia.it/wps/portal/istituzionale/HP/istituzione/Giunta/sedute-delibere-giunta-regionale/DettaglioDelibere/delibera-5830-legislatura-11.
  3. (3) Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., Degenhardt L. (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet, 378(9791): 571-83.
  4. (4) Sperle I., Hedrich D., Palczak K., Singleton N., Zimmermann R. (2018). Barriers to HCV Testing in Drug Treatment Services for People who Inject Drugs. Poster EMCCDA Lisbon.
  5. (5) EMCDDA (2019). Hepatitis C new model of care for drug services. -- Text available at the website: www.emcdda.europa.eu/drugs-library/hepatitis-c-new-models-care-drugs-services_en.
  6. (6) Fagiuoli S., Pasulo L., Maggiolo F., Spinella R., Del Poggio P., Boldizzoni R., Di Marco M., Aronica A., Benedetti C., Correale P., Garavaglia C., Nicora C. (2019). Economic Evaluation of Different Organizational Models for the Management of Patients with Hepatitis C. Farmacoeconomia. Health economics and therapeutic pathways, 20(1). Text available at the website: https://doi.org/10.7175/fe.v20i1.1374.
  7. (7) Cepheid (2022). -- Text available at the website: www.cepheid.com/en/tests/Virology/Xpert-HCV-Viral-Load.
  8. (8) Barocas J.A., Linas B.P., Kim A.Y., Fangman J., Westergaard R.P. (2016). Acceptability of Rapid Point-of-Care Hepatitis C Tests Among People Who Inject Drugs and Utilize Syringe-Exchange Programs. Open Forum Infect Dis., 3(2): ofw075.
  9. (9) AIFA (2019). -- Text available at the website: www.aifa.gov.it/aggiornamento-epatite-c.
  10. (10) Nevola R., Rosato V., Conturso V., Perillo P., Le Pera T., Del Vecchio F., Mastrocinque D., Pappalardo A., Imbriani S., Delle Femine A., Piacevole A., Claar E. (2022). Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies. Biology, 11: 805.
  11. (11) Frankova S., Jandova Z., Jinochova G., Kreidlova M., Merta D., Sperl J. (2021). Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J, 18: 69. -- Text available at the website: https://doi.org/10.1186/s12954-021-00519-y.
  12. (12) Falade-Nwulia O., Sulkowski M.S., Merkow A., Latkin C., Mehta S.H. (2018). Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat., 25(3): 220-227.

Liliana Praticò, Roberta Marenzi, Nicola Ghidelli, Andrea Corbetta, Marta Vairini, Michela Franzin, Stefano Fagiuoli, Paolo Donadoni, Marco Riglietta, Il SerD come Point of Care per infezione da HCV: è possibile in "MISSION" 58/2022, pp 12-17, DOI: 10.3280/mis58-2022oa14792